Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 10/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14945579 | 0.87 | RBP4 (0.61) | RBP4HTR2CDRD3GRM2 | |
| SCHEMBL3766143 | 0.84 | RBP4 (0.46) | RBP4HTR2CHTR2AHTR2BDRD3 | |
| SCHEMBL2783328 | 0.84 | DRD2 (0.57) | DRD3GRM2 | |
| SCHEMBL3759928 | 0.83 | DRD3 (0.46) | RBP4HTR2CHTR2ADRD3GRM2 | |
| SCHEMBL27684074 | 0.83 | SLC18A3 (0.49) | RBP4DRD3GRM2 | |
| SCHEMBL3768131 | 0.81 | HTR6 (0.43) | HTR2CHTR2BDRD3GRM2 | |
| SCHEMBL2781323 | 0.81 | DRD3 (0.45) | RBP4DRD3GRM2 | |
| SCHEMBL8279877 | 0.81 | DRD3 (0.45) | RBP4DRD3GRM2 | |
| SCHEMBL5501668 | 0.80 | CYP2D6 (0.40) | RBP4HTR2CHTR2AHTR2BDRD3 | |
| SCHEMBL24158043 | 0.79 | RBP4 (0.46) | RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851629-B2 | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-12-14 | — | — | US | claimed |
| EP-1768958-B1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2009-11-18 | — | — | EP | claimed |
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-08-02 | — | — | US | claimed |
| US-7851629-B2 | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-12-14 | — | — | US | disclosed |
| US-7851629-B2 | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-12-14 | — | — | US | disclosed |
| US-7851629-B2 | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-12-14 | — | — | US | disclosed |
| EP-1768958-B1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2009-11-18 | — | — | EP | disclosed |
| EP-1768958-B1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2009-11-18 | — | — | EP | disclosed |
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-08-02 | — | — | US | disclosed |
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-08-02 | — | — | US | disclosed |
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-08-02 | — | — | US | disclosed |
| EP-1768958-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2005121088-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | DRD2, DRD4, HTR4 | RBP4 2559/4885HTR2C 11/4885HTR2A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.